Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib

被引:0
作者
Chun-wei Xu
Wen-xian Wang
Yan-ping Chen
Yu Chen
Wei Liu
Li-hua Zhong
Fang-fang Chen
Wu Zhuang
Zheng-bo Song
Xiao-hui Chen
Yun-jian Huang
Yan-fang Guan
Xin Yi
Tang-feng Lv
Wei-feng Zhu
Jian-ping Lu
Xiao-jiang Wang
Yi Shi
Xian-dong Lin
Gang Chen
Yong Song
机构
[1] Fujian Cancer Hospital,Department of Pathology
[2] Fujian Medical University Cancer Hospital,Department of Chemotherapy
[3] Zhejiang Cancer Hospital,Department of Medical Oncology
[4] Fujian Cancer Hospital,Department of Thoracic Surgery
[5] Fujian Medical University Cancer Hospital,Department of Respiratory Medicine
[6] Fujian Cancer Hospital,undefined
[7] Fujian Medical University Cancer Hospital,undefined
[8] Geneplus-Beijing,undefined
[9] Jinling Hospital,undefined
来源
Journal of Translational Medicine | / 16卷
关键词
NSCLC; ALK; VENTANA IHC; RT-PCR; NGS; Crizotinib;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [41] Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib
    Davis, K. L.
    Kaye, J. A.
    Masters, E. T.
    Iyer, S.
    CURRENT ONCOLOGY, 2018, 25 (01) : E40 - E49
  • [42] Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
    Amrane, Karim
    Campedel, Luca
    Le Meur, Coline
    Abgral, Ronan
    Kharroubi, Dris
    Cadranel, Jacques
    FRONTIERS IN MEDICINE, 2021, 8
  • [43] HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer and Response to Crizotinib
    Wang, W.
    Xu, C.
    Zhang, Q.
    Zhuang, W.
    Zhu, Y.
    Chen, Y.
    Fang, M.
    Chen, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1032 - S1032
  • [44] Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer
    Lu, Shun
    Zhang, Jie
    Ye, Ming
    Wang, Baoai
    Wu, Bin
    PHARMACOGENOMICS, 2016, 17 (09) : 985 - 994
  • [45] ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
    Scagliotti, Giorgio
    Stahel, Rolf A.
    Rosell, Rafael
    Thatcher, Nick
    Soria, Jean-Charles
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (07) : 961 - 973
  • [46] Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
    Deng, Huiyan
    Li, Bin
    Li, Lina
    Peng, Jingcui
    Lv, Tongshuai
    Liu, Yueping
    Ding, Cuimin
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [47] A PROSPECTIVE PROTOCOL FOR SIMULTANEOUS GENOMIC TESTING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Lopez-Rios, Fernando
    Conde, Esther
    Angulo, Barbara
    Martinez, Rebeca
    Mcgready, Claire
    O'Hara, Graeme
    Anderson, Neil
    Maxwell, Perry
    Salto-Tellez, Manuel
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1074 - S1074
  • [48] Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib
    Ma, Di
    Zhang, Yan
    Xing, Puyuan
    Hao, Xuezhi
    Wang, Mengzhao
    Wang, Yan
    Shan, Li
    Xin, Tao
    Liang, Hongge
    Du, Yang
    Zhang, Zhaohui
    Liang, Li
    Li, Junling
    THORACIC CANCER, 2019, 10 (05) : 1213 - 1219
  • [49] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Ricciuti, Biagio
    De Giglio, Andrea
    Mecca, Carmen
    Arcuri, Cataldo
    Marini, Sabrina
    Metro, Giulio
    Baglivo, Sara
    Sidoni, Angelo
    Bellezza, Guido
    Crino, Lucio
    Chiari, Rita
    MEDICAL ONCOLOGY, 2018, 35 (05)
  • [50] Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
    Biagio Ricciuti
    Andrea De Giglio
    Carmen Mecca
    Cataldo Arcuri
    Sabrina Marini
    Giulio Metro
    Sara Baglivo
    Angelo Sidoni
    Guido Bellezza
    Lucio Crinò
    Rita Chiari
    Medical Oncology, 2018, 35